Plain-English translation of NCT05878769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people with COPD (chronic obstructive pulmonary disease) who have already completed a year-long initial trial of . Researchers want to learn more about how safe this medication is when people use it for a longer period of time, and whether it continues to help their lung function. You would receive the medication by injection under the skin every two weeks.
The first year of testing showed promising results, but doctors need to understand how this treatment works over time and whether it remains safe with long-term use. This extended study helps them gather that important safety information for people living with COPD.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would continue receiving the same injection every two weeks until the study ends. The study team will monitor you for any side effects and check how your lungs are responding to the treatment through regular clinic visits. This is a longer-term commitment than the initial trial, allowing researchers to build a clear picture of how safe and effective this medication is over time.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States